BioGene Therapeutics Appoints Patroski J. Lawson to Board of Directors
PreveCeutical Medical announced that its subsidiary BioGene Therapeutics has appointed Patroski J. Lawson as an independent director effective December 6, 2024. According to CEO Stephen Van Deventer, Lawson brings extensive experience in government affairs across local, state, federal, and global levels, particularly within the healthcare sector. The company expects his strategic insights and leadership to strengthen their governance and advocacy efforts as they navigate the regulatory landscape in developing innovative therapies.
PreveCeutical Medical ha annunciato che la sua sussidiaria BioGene Therapeutics ha nominato Patroski J. Lawson come direttore indipendente, con effetto dal 6 dicembre 2024. Secondo il CEO Stephen Van Deventer, Lawson porta un'ampia esperienza negli affari governativi a livello locale, statale, federale e globale, in particolare nel settore sanitario. L'azienda si aspetta che le sue intuizioni strategiche e la sua leadership rafforzino i loro sforzi di governance e di advocacy mentre navigano nel contesto normativo nello sviluppo di terapie innovative.
PreveCeutical Medical anunció que su filial BioGene Therapeutics ha nombrado a Patroski J. Lawson como director independiente, efectivo a partir del 6 de diciembre de 2024. Según el CEO Stephen Van Deventer, Lawson aporta una amplia experiencia en asuntos gubernamentales a nivel local, estatal, federal y global, particularmente en el sector de la salud. La compañía espera que sus perspectivas estratégicas y liderazgo fortalezcan sus esfuerzos de gobernanza y defensa mientras navegan el panorama regulatorio en el desarrollo de terapias innovadoras.
PreveCeutical Medical는 자회사인 BioGene Therapeutics가 Patroski J. Lawson을 독립 이사로 임명했다고 발표했습니다. 임명은 2024년 12월 6일에 발효됩니다. CEO Stephen Van Deventer에 따르면 Lawson은 지역, 주, 연방 및 글로벌 차원에서 정부 업무에 대한 광범위한 경험을 가지며, 특히 의료 분야에서 두드러집니다. 회사는 그의 전략적 통찰력과 리더십이 혁신적인 치료법 개발에서 규제 환경을 탐색하는 데 있어 그들의 거버넌스 및 옹호 노력을 강화할 것이라고 기대하고 있습니다.
PreveCeutical Medical a annoncé que sa filiale BioGene Therapeutics a nommé Patroski J. Lawson en tant que directeur indépendant à compter du 6 décembre 2024. Selon le PDG Stephen Van Deventer, Lawson possède une vaste expérience dans les affaires gouvernementales à l'échelle locale, étatique, fédérale et mondiale, en particulier dans le secteur de la santé. L'entreprise s'attend à ce que ses idées stratégiques et son leadership renforcent leurs efforts de gouvernance et de plaidoyer alors qu'ils naviguent dans le paysage réglementaire lié au développement de thérapies innovantes.
PreveCeutical Medical gab bekannt, dass ihre Tochtergesellschaft BioGene Therapeutics Patroski J. Lawson mit Wirkung zum 6. Dezember 2024 zum unabhängigen Direktor ernannt hat. Laut CEO Stephen Van Deventer bringt Lawson umfangreiche Erfahrungen in Regierungsangelegenheiten auf lokaler, staatlicher, bundesstaatlicher und globaler Ebene mit, insbesondere im Gesundheitssektor. Das Unternehmen erwartet, dass seine strategischen Einblicke und seine Führung ihre Governance- und Advocacy-Bemühungen stärken, während sie sich im regulatorischen Umfeld der Entwicklung innovativer Therapien bewegen.
- Addition of board member with extensive healthcare sector regulatory experience
- Strengthened governance structure through independent director appointment
- None.
Vancouver, British Columbia--(Newsfile Corp. - December 9, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed Patroski J. Lawson as an independent director effective on 6 December, 2024.
Stephen Van Deventer, CEO of BioGene, commented:
"We are honored to welcome Patroski Lawson to our Board of Directors. His extensive experience in government affairs across local, state, federal, and global levels, particularly within the healthcare sector, will be invaluable as we navigate the complex regulatory landscape and advance our mission to deliver innovative therapies. Patroski's strategic insights and leadership will significantly enhance our governance and advocacy efforts."
About Patroski J. Lawson:
Patroski Lawson brings over 25+ years of experience in government affairs, spanning both public and private sectors. He began his career as a regional representative for U.S. Senator Paul D. Coverdell, liaising with government officials and leading anti-drug outreach initiatives.
In the private sector, Patroski managed political involvement programs and corporate political action committees (PACs) at The Home Depot. He further honed his expertise in healthcare government affairs at Solvay Pharmaceuticals, Abbott, and Lundbeck, leading lobbying and advocacy efforts in Brussels, Washington D.C., and various U.S. state capitals.
Notably, Patroski was instrumental in securing a
In 2017, he founded KPM Group DC, a concierge public affairs firm providing strategic guidance to clients in need of comprehensive government affairs solutions.
Patroski holds a B.S. in Political Science with a concentration in Urban Geography and an M.S.P. in Urban and Regional Planning, both from The Florida State University.
Patroski J. Lawson remarked on his appointment:
"I am thrilled to join BioGene's Board of Directors and contribute to the Company's mission of advancing transformative therapies. BioGene's dedication to addressing critical unmet medical needs aligns with my passion for strategic advocacy and public affairs. I look forward to supporting the Company's growth and success."
About PreveCeutical Medical Inc.
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit www.PreveCeutical.com, follow us on Twitter: http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.
About BioGene Therapeutics Inc.
BioGene Therapeutics Inc. ("BioGene") is a Texas-based life sciences company focused on advancing innovative therapies in metabolic health and gene-based treatments. As a key component of BioGene's expansion, BioGene Australia operates as a wholly-owned subsidiary of BioGene in Texas, leveraging the strategic benefits of Australia's
On Behalf of the Board of Directors,
PreveCeutical Medical Inc. & BioGene Therapeutics Inc.
"Stephen Van Deventer"
Chairman & Chief Executive Officer
For further information, please contact:
Stephen Van Deventer
(604) 306-9669
info@PreveCeutical.com
Forward-Looking Statements:
This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding receipt of regulatory and other consents and approvals for the Acquisition; PreveCeutical, PreveCeutical Australia, and BioGene completing the Acquisition as contemplated by the Agreement; PreveCeutical receiving the necessary regulatory and other consents and approvals for the Distribution; and PreveCeutical completing the Distribution as contemplated above. The forward-looking statements reflect management's current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements including adverse market conditions and other factors beyond the control of the parties. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include general market conditions and other factors beyond the control of the Company; regulations and policies affecting the biotechnology or pharmaceutical industry adversely affecting the future results or performance of PreveCeutical or BioGene; the Company's failure to obtain the required consents and approvals for the Acquisition and the Distribution; and the Company determining that the Distribution is not an optimal strategy following tax and business consultations. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/232911
FAQ
When did Patroski J. Lawson join BioGene Therapeutics' Board of Directors?
What is PreveCeutical Medical's stock symbol on the OTCQB?
What experience does Patroski Lawson bring to BioGene Therapeutics?
